Pegaspargasecombined with concurrent radiotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: A two-center phase II study.

CONCLUSION: Preliminary data indicate that pegaspargase combined with concurrent radiotherapy for newly diagnosed patients with nasal ENKTL was efficacious and well tolerated. (This study was registered at www.chictr.org, the Clinical Trial Registration Number was ChiCTR-OIC-15007662.) IMPLICATIONS FOR PRACTICE: This clinical trial, evaluating the efficacy and toxicity of concurrent chemoradiotherapy by using single-drug pegaspargase for patients with ENKTL in stage IE to IIE,showed pegaspargase combined with concurrent radiotherapy was efficacious and well tolerated. Pegaspargase has a long half-life and is easy to administer via intramuscular injection. Consequently, pegaspargase combined with concurrent radiotherapy for ENKTL patients can be completed in the outpatient clinic. PMID: 32627928 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32627928?dopt=Abstract

Source: The Oncologist - July 5, 2020 Category: Cancer & Oncology Authors: Wang H, Wang L, Li C, Wuxiao Z, Chen G, Luo W, Lu Y Tags: Oncologist Source Type: research